Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous Melanoma  by Greene, Victoria R. et al.
Frequencies of NRAS and BRAF Mutations Increase
from the Radial to the Vertical Growth Phase in
Cutaneous Melanoma
Victoria R. Greene1, Marcella M. Johnson2, Elizabeth A. Grimm1 and Julie A. Ellerhorst1
A lack of consensus exists with regards to the relative rates of NRAS and BRAF mutations in the radial (RGP) and
vertical (VGP) growth phases of individual melanoma tumors. This study was conducted to test the hypothesis
that mutations are acquired with progression from RGP to VGP. Using laser capture microdissection, pure tumor
DNA was obtained from 15 in situ melanomas, and from the RGP and VGP of 29 invasive tumors. NRAS exon 2
and BRAF exon 15 DNA were amplified by PCR and sequenced. Mutations were present in 6 of 15 in situ
melanomas (40%). Of 29 invasive tumors, 16 exhibited RGP mutations (55.2%); 22 showed VGP mutations
(75.9%). Paired RGP/VGP mutation analysis revealed a trend toward discordance in the distribution of mutations,
favoring VGP localization (P¼ 0.07). Of 15 samples, 12 with mutations in both phases had an increased
proportion of mutated DNA in the VGP, measured on DNA chromatograms (P¼ 0.08). Limitations of this study
include a relatively small sample cohort selected for technical reasons from a larger population, presenting the
risk of selection bias. These concerns notwithstanding our findings support the hypothesis that NRAS and BRAF
mutations increase with tumor progression from superficial to invasive disease.
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INTRODUCTION
Cancer develops through a succession of genetic alterations
involving pathways which regulate key cellular functions
such as apoptosis, growth signaling, DNA repair, and
angiogenesis (Hanahan and Weinberg, 2000; Hahn and
Weinberg, 2002). Clark has delineated clinical and histo-
pathologic stages of progression for cutaneous melanoma,
from precursor neoplasm to in situ melanoma (also known as
the radial growth phase or RGP) to invasive or vertical growth
phase (VGP) tumor (Clark et al., 1984). As molecular and
genetic abnormalities are identified in melanomas, research-
ers attempt to identify their origins along the clinical and
histopathologic progression model. Mutations of RAS and
RAF genes, particularly NRAS exon 2 and BRAF exon 15,
have been identified with high frequency in nevi, cutaneous
melanomas, and melanoma metastases (Davies et al., 2002;
Pollock et al., 2003; Uribe et al., 2003; Houben et al., 2004;
Kumar et al., 2004; Akslen et al., 2005; Goydos et al., 2005;
Edlundh-Rose et al., 2006; Goel et al., 2006). These
mutations lead to amino acid substitutions within the NRAS
and BRAF proteins, resulting in constitutive activation of
growth signaling through the mitogen-activated protein
kinase pathway (Beeram et al., 2005).
A number of studies have been conducted to establish the
stage of melanoma at which these mutations are acquired.
There is general agreement that pure in situ melanomas carry
a low prevalence of NRAS and BRAF mutations compared
with rates seen in other progression phases (Dong et al.,
2003; Yazdi et al., 2003; Poynter et al., 2006). In contrast,
data from more advanced melanomas, that is invasive
primary tumors and metastases, have been inconclusive,
with some studies showing acquisition of mutations from
RGP to VGP and beyond, whereas others report stable
genotypes across all progression stages of an individual tumor
(Demunter et al., 2001; Omholt et al., 2002, 2003; Dong
et al., 2003). Differences in patient populations, methods of
tumor acquisition, as well as variation in mutation identifica-
tion procedures and types of mutations tested limit compar-
ison between studies. As a result, the question of whether
NRAS and BRAF mutations occur at the earliest tumor stages
or are acquired with progression remains unanswered.
This study attempts to clarify the literature by comparing
NRAS and BRAFmutation rates in pure in situ tumors, and the
RGP and VGP of primary invasive melanomas. Methods
incorporate laser capture microdissection to assure maximum
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purity of tumor DNA. Our results show an incremental
increase in mutation rates between in situ melanomas, the
RGP of invasive melanomas, and the VGP of the same
tumors. In addition, we demonstrate, in tumors with
mutations in both phases, an increase in the percentage of
mutated DNA in the VGP portion of the tumor. We conclude
that NRAS exon 2 and BRAF exon 15 mutations are acquired
as melanomas progress from an in situ to an invasive stage.
RESULTS
Study population
The study objective required the identification and micro-
dissection of melanomas with distinct RGP and VGP. To this
end, 285 consecutive entries into the Melanoma Tumor Bank
through the M. D. Anderson Cancer Center Melanoma
SPORE were screened. Within this group, there were 187
tumors in which both the RGP and VGP could be identified.
For an invasive melanoma to qualify for this study, it was
required that both growth phases be least 1mm in least
dimension (for adequate tumor cell numbers) and that the
two phases be distinct from each other, that is sites of
overlapping RGP and VGP were avoided. In all, 34 cases
were identified and microdissected as separate RGP and VGP
samples. A complete set of sequence results, consisting of
BRAF exon 15 and NRAS exon 2 for both growth phases, was
obtained for 29 of the 34 RGP/VGP pairs.
Seventeen in situ melanomas were identified from the
same sample set. Two of these were acral lentigenous in situ
melanomas and were excluded from the analysis based on
evidence in the literature that the development of this subset
of cutaneous melanomas follows a different genetic path than
that of melanomas which develop in the more common sites.
Therefore, 15 in situ tumors were analyzed, all of which
yielded full sequence results.
Overall mutation rates
DNA sequences for NRAS exon 2 and BRAF exon 15 were
obtained for the 15 in situmelanomas and 29 paired RGP and
VGP samples described above (Figure 1). Clinical character-
istics of the study population are given in Table 1.
Mutations were identified in 6 of the 15 in situ melanomas
(40%). Five of these were BRAF T1799A point mutations. In
addition, one case had both an NRAS A182G and BRAF
VGP
100 µm
RGP
Figure 1. Microdissection of melanoma cells from the radial and vertical
growth phases of a cutaneous melanoma. The sample represents no. 26 in
Table 2. Microdissected tumor cells from the VGP (left) had invaded the
dermis, whereas RGP tumor cells (right) were localized within the epidermis.
Hematoxylin and eosin staining was modified for laser capture
microdissection; scale bar¼ 100 mm.
Table 1. Clinical features of patients and tumors
Characteristic
Invasive melanomas,
n (%)
In situ melanomas,
n (%)
Age
p50 12 (41.4) 6 (40.0)
450 17 (58.6) 9 (60.0)
Gender
Female 9 (31.0) 6 (40.0)
Male 20 (69.0) 9 (60.0)
Location
Trunk 11 (37.9) 7 (46.7)
Upper extremity 10 (34.5) 3 (20.0)
Lower extremity 6 (20.7) 4 (26.7)
Head and neck 2 (6.9) 1 (6.6)
Melanoma type
Superficial
spreading
29 (100.0) 4 (26.7)
Lentigo maligna 0 (0) 3 (20.0)
Not specified 0 (0) 8 (53.3)
Breslow thickness
o1.0mm 13 (44.8)
1.1–2.0mm 13 (44.8)
2.1–3.0mm 3 (10.4)
43.0mm 0 (0)
Clark level
I 0 (0)
II 2 (6.9)
III 17 (58.6)
IV 10 (34.5)
V 0 (0)
Ulceration
Yes 4 (13.8)
No 25 (86.2)
Metastasis
Yes 4 (13.8)
No 25 (86.2)
1484 Journal of Investigative Dermatology (2009), Volume 129
VR Greene et al.
NRAS, BRAF Mutations Increase from RGP to VGP
GT1798AG mutation. Of the 29 invasive melanomas, 23
(79.3%) carried mutations, a proportion significantly higher
than that of the in situ tumors (P¼0.009, w2). Sixteen tumors
harbored mutations in the RGP (55.2%) and twenty-two in the
VGP (75.9%). There were 9 NRAS and 16 BRAF mutations
including 2 tumors in which both exons carried a mutation.
Paired RGP/VGP mutation rates
A listing of DNA sequence results for the 29 RGP/VGP pairs is
shown in Table 2. Nine tumors (31.0%) showed discordance
in genotype between the two growth phases. Eight of these
carried wild-type DNA in the RGP and mutated DNA in
the VGP. A single discordant pair had the reverse pattern, that
is mutated RGP DNA and wild-type VGP DNA. The exact
McNemar’s test was used to determine if the apparent
skewing of discordance toward acquisition of mutations in
the VGP was significant. (The presence in sample no. 4 of
both NRAS and BRAF mutations in different locations
precluded assignment to the categories required for this test;
this sample was excluded from the analysis). Results yielded a
P-value of 0.07, approaching significance and supporting the
hypothesis of a gain in mutations accompanying dermal
invasion of the tumor.
Proportions of mutated DNA in concordant RGP/VGP pairs
The analysis above included only pairs in which one of the
growth phases was entirely wild type. The results, supporting
the acquisition of mutations with progression, suggested that
in cases where mutations existed in both growth phases, the
mutation rate would be higher in cells from the VGP. To
explore this possibility, we examined the sequencing
chromatograms to estimate the relative amounts of mutated
and wild-type DNA in a given tumor sample. This approach
was first validated using DNA from melanoma cells lines that
carry only mutated (A375) or wild-type (MeWo) BRAF DNA.
Mixtures of known concentrations of DNA from the two cell
lines were prepared to obtain 0, 25, 50, 75, and 100%
mutated DNA. The mixtures were amplified by PCR and
sequenced using the same procedures as for the melanoma
tissue samples. As shown in Figure 2a, the proportions of
mutated and wild-type nucleotide peaks on the DNA
sequencing chromatograms correspond to their respective
proportions in the cell line DNA mixtures.
Having validated this approach, DNA chromatogram
measurements comparing the percentage of mutated DNA
in the RGP/VGP pairs were made for the 15 cases in which
both growth phases were mutated (sample nos. 10–23 and 4
in Table 2). Representative pairs with their respective
mutation rates are shown in Figure 2b; results for all the 15
cases are charted in Figure 3. Of the 15 tumors, 12 (80%) had
an increased percentage of mutated DNA in the VGP
compared with the RGP, the increment ranging from 4.8 to
52.4%. The mean percentage of mutated DNA was 39.4% for
RGP tumors and 52% for VGP tumors. Results of paired t-test
analysis of these data approached significance with a P-value
of 0.08. Although the actual percentages reported should be
viewed as approximations, these findings support the overall
conclusion of an increased proportion of mutated cells in the
VGP and are in agreement with the hypothesis of acquisition
of mutations in the course of melanoma progression.
DISCUSSION
The results of this study demonstrate that mutations of NRAS
exon 2 and BRAF exon 15 increase in frequency with
progression of primary melanoma. We report an incremental
increase in NRAS and BRAF mutation rates along the
melanoma progression model from purely in situ melanomas,
to the RGP of invasive melanomas, to the VGP of invasive
melanomas. Upon examination of mutations within the RGP
and VGP of individual tumors, eight of the nine discordant
cases carried a mutation in the VGP that was not identified in
the RGP. Finally, 80% of tumors in which both growth phases
were mutated showed increased proportions of mutated DNA
in the VGP compared with the RGP.
Table 2. Mutational status of paired radial and vertical
growth phase tumor samples
NRAS exon 2 BRAF exon 15
Sample RGP VGP RGP VGP
Discordant
1 WT C181A WT WT
2 WT C181A WT WT
3 WT A182G WT GT1798AA
4 WT C181A T1799A T1799A
5 WT WT WT T1799A
6 WT WT WT T1799A
7 WT WT WT T1799A
8 WT WT WT TG1799AA
9 WT WT T1799A WT
Concordant
10 C181A C181A WT WT
11 C181A C181A WT WT
12 A182G A182G WT WT
13 AA182TG AA182TG WT WT
14 A183T A183T WT WT
15 WT WT T1790A T1790A
16 WT WT T1799A T1799A
17 WT WT T1799A T1799A
18 WT WT T1799A T1799A
19 WT WT T1799A T1799A
20 WT WT T1799A T1799A
21 WT WT T1799A T1799A
22 WT WT T1799A T1799A
23 WT WT T1799A T1799A
24 WT WT WT WT
25 WT WT WT WT
26 WT WT WT WT
27 WT WT WT WT
28 WT WT WT WT
29 WT WT WT WT
RGP, radial growth phase; VGP, vertical growth phase; WT, wild type.
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Variations in mutation rates between studies notwithstand-
ing our results are in general agreement with the work of
other investigators who found lower NRAS and BRAF
mutation rates in purely in situ melanomas compared with
invasive melanomas (Ball et al., 1994; Dong et al., 2003;
Yazdi et al., 2003; Poynter et al., 2006). In contrast, our data
describing mutational gain from RGP to VGP of the same
tumor diverge from findings of other studies employing
similar methodology. Omholt et al. (2002, 2003) compared
the presence of NRAS and BRAF mutations in the RGP and
VGP of invasive melanomas and found that all pairs carried
identical mutations. Notably, the samples were selected for
the presence of mutations in the VGP and for a patient history
of distant metastasis. Similarly, Demunter et al. (2001)
reported concordance of NRAS mutations in 25 RGP/VGP
pairs. As in the Omholt studies, the samples were retro-
spectively selected for VGP mutations and at least one-third
of the patients had Stage IV disease. Thus, the 31% RGP/VGP
discordance rate that we report differs substantially from the
current literature. Although the reason for this discrepancy is
not entirely clear, part of the explanation may lie in
differences in the clinical features of the melanomas
examined. The median Breslow thickness of tumors in the
two Omholt studies was 2.55 and 2.60mm, considerably
thicker than the median Breslow thickness of 1.25mm for our
samples. In addition, only 4 of the 29 patients (13.8%) in our
prospectively followed cohort have developed regional
metastasis and currently none have distant disease. It is
possible that regional and distant spread is preceded by
aggressive early acquisition of mutations in the RGP,
accounting for the lack of wild-type RGP samples in those
predominantly Stage IV patient populations. It appears, then,
that case selection may influence the results and conclusions
of this type of analysis. Although selected based upon
technical rather than clinical criteria, our study population,
such as those in the previous reports, was chosen from a
considerably larger patient group and is therefore possibly
subject to selection bias. These data should be interpreted
with precaution in mind.
The most important difference between our report and
those described above is the interpretation of concordant
cases, representing 69 and 100% of subjects, respectively. To
our knowledge, our study is the first to attempt formal
quantitation of mutated DNA within RGP and VGP pairs.
Previous reports, taking a ‘‘yes or no’’ approach, have
considered any amount of mutated DNA in the RGP and
VGP to be equivalent, leading to the conclusion that
mutations are not acquired between the growth phases. In
contrast, by our approach of measuring chromatogram peaks,
we found evidence of a gain of mutations in the VGP.
Moreover, we predict that many of the tumors in our study
with wild-type DNA in both growth phases actually do carry
mutations, albeit at levels below the sensitivity of the
currently utilized PCR methods. A more sensitive method
would likely reveal these low-level mutation rates and
demonstrate the same trend toward acquisition of mutations
in the VGP. Moreover, the previous studies using the ‘‘yes or
0%
28% 63% 43% 77% 46% 70%
RGPVGPRGP VGPRGP VGP
% Mutated
DNA
% Mutated
DNA
25% 50% 75% 100%
Figure 2. Acquisition of mutations in the VGP as determined by sequencing chromatograms. (a) Predetermined amounts of BRAF T1799A mutated DNA were
mixed with wild-type DNA. The contribution of the mutated DNA to the chromatogram reflects the percentage in the DNA mixture. The red peak (T) is
wild type; the green peak A represents the single nucleotide mutation. (b) Three representative cases of DNA isolated from paired RGP/VGP samples, amplified
with primers for BRAF exon 15, and sequenced. Measurement of the chromatograms reveals an increased percentage of T1799A mutations in the VGP DNA.
–80 –60 –40 –20 0 20 40 60 80
NRAS
VGP > RGPRGP > VGP
BRAF
Figure 3. Differences in the percentage of mutated DNA between the RGP
and VGP of individual melanomas. Included in this chart are 15 tumors with
identical mutations in both growth phases, representing samples no. 4 and
nos. 10–23 from Table 2. Entries are calculated as (% mutated VGP DNA)
minus (% mutated RGP DNA). An increased proportion of mutated DNA is
found in the VGP of 12 of the 15 tumors.
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no’’ approach and reporting mutational identity between the
RGP and VGP of the same tumors may simply be showing
that an RGP with a mutation rate exceeding the detection
threshold will be associated with a VGP also above the
threshold. In the absence of a quantitative approach, these
studies will fail to detect actual differences in the amount of
mutated DNA between the two phases and draw a conclu-
sion of equivalency.
Despite the high quality of microdissection provided by
the laser capture methodology (Simone et al., 1998), there
remains the possibility of contamination of RGP melanoma
cells with keratinocytes during the dissection process, leading
to an artificial lowering of the RGP mutation rate. Accord-
ingly, steps were taken to avoid contamination, such as
leaving a rim of melanoma cells at the microdissection border
when possible, and using the smallest laser spot size. Review
of the microdissected RGP samples suggests a contamination
rate of less than 5%. Furthermore, there is likely to be a
similar rate of sporadic contamination of VGP melanoma
cells with lymphocytes and endothelial cells, balancing the
contribution of normal cells to the RGP preparation. Thus,
after taking into account these variables, we believe that the
presence of incidental DNA from normal cells did not
significantly alter our data or conclusions.
On the basis of our findings, two non-mutually exclusive
paradigms exist for the acquisition of mutations in melanoma
as cells progress from RGP to VGP. In the first scenario, NRAS
and BRAF mutations originate in the RGP. The cells bearing
these mutations are phenotypically aggressive and more
likely to invade the dermis, thus representing a higher
percentage of VGP tumor cells. The second model suggests
that mutations are not involved in the transition from
RGP to VGP, but that mutational pressures are stronger in
the dermis than in the epidermis. Unfortunately, the ability to
dissect these processes in individual tumors is hampered by
the lack of clearly understood mechanisms driving the
development of NRAS and BRAF mutations. Processes
such as damage from UVR and reactive oxygen species
have been proposed, and it is reasonable to speculate that
these stimuli may predominate in one compartment or
another along the path of melanoma progression (Gilchrest
et al., 1999; Meyskens et al., 2004; Fruehauf and Meyskens,
2007). It is also clear from our data and those of others
that some BRAF and NRAS wild-type cells are capable of
invading the dermis. It is likely that the wild-type cells
present in the VGP are biologically distinct from the
wild-type cells in the RGP, possessing one or more yet to
be identified features that promote invasiveness. It appears,
then, that NRAS and BRAF mutations are not the entire story
and that other invasion-promoting genotypes remain to be
discovered.
In conclusion, we have shown that NRAS and
BRAF mutations increase with progression of primary
melanoma. These findings, if confirmed, may shed light on
important aspects of the biology of this disease. Further
acquisition of mutations in advanced stages of melanoma will
be a focus of interest as we continue to follow our patient
cohort.
MATERIALS AND METHODS
Study population
The study was approved by the M. D. Anderson Cancer Center
Institutional Review Board and conducted in accordance with
Health Insurance Portability and Accountability Act, and the
Declaration of Helsinki Principles. Written informed consent was
obtained from all the participants. Fifteen in situ and thirty-four
invasive primary cutaneous melanomas were selected from con-
secutive entries into the M. D. Anderson Cancer Center Melanoma
Program Informatics, Tissue Resource, and Pathology Core. Selec-
tion of invasive tumors was based on the criterion of the presence of
RGP and VGP in amounts sufficient for PCR amplification and DNA
sequencing (approximately 1,000 cells per growth phase).
DNA extraction and amplification
Three 5-mm-thick, formalin-fixed, paraffin-embedded tissue sections
per melanoma case were stained using solutions of xylenes
(5minutes), xylenes (5minutes), 100% ethanol (30 seconds), 100%
ethanol (30 seconds), 95% ethanol (30 seconds), sterile deionized
distilled water (15 seconds), Mayer’s hematoxylin (15 seconds), 0.5%
lithium carbonate (30 seconds), sterile deionized distilled water
(30 seconds), 70% ethanol (30 seconds), alcoholic eosin (30 sec-
onds), 95% ethanol (15 seconds), 100% ethanol (30 seconds), 100%
ethanol (30 seconds), xylenes (1minute), xylenes (1minute). Fresh
solutions were prepared for each case. Laser capture microdissection
of tumor cells was performed by a board-certified pathologist
(V.R.G.). A minimum of 1,000 melanoma cells per RGP and VGP
were dissected as separate samples using the PixCell II Laser Capture
Microdissection System (Arcturus, Mountain View, CA) according to
manufacturer’s instructions. Dissected cells were incubated for
72 hours at 37 1C in 50–100ml of lysis buffer containing 10mM
Tris-HCl (pH 8.0), 1% Tween-20, 1mM EDTA, and 0.04% Proteinase
K. The sample was centrifuged for 5minutes at 14,000 r.p.m. and
then heated at 95 1C for 8minutes.
PCR was performed using the GeneAmp Gold PCR Reagent Kit
(Applied Biosystems, Foster City, CA). Primers and conditions for
NRAS exon 2 and BRAF exon 15 were obtained from Sigma Genosys
(The Woodlands, TX). Primer sequences (14) and conditions are
listed below:
NRAS exon 2: forward: 50-GGTGAAACCTGTTTGTTGGA-30; re-
verse: 50-AACCTAAAACCAACTCTTCCCA-30; 95 1C 45 seconds, 57 1C
45 seconds, 72 1C 60seconds; 40 cycles; magnesium chloride 2.5mM.
BRAF exon 15: forward: 50-TCATAATGCTTGCTCTGATAGGA-30;
reverse: 50-GGCCAAAAATTTAATCAGTGGA-30; 94 1C 30 seconds,
57 1C 60 seconds, 72 1C 60 seconds; 40 cycles; magnesium chloride
1.5mM.
PCR products were purified using QIAquick PCR Purification Kit
(Qiagen, Valencia, CA) according to manufacturer’s instructions.
The purified products were sequenced in both forward and reverse
directions by M. D. Anderson Cancer Center DNA Core facility using
an ABI Prism 3100 DNA Genetic Analyzer (Applied Biosystems) and
Big Dye version 3.1 dye terminator chemistry (Applied Biosystems).
Estimation of the proportion of mutated sample DNA
Proportions of mutated DNA were calculated by physically measur-
ing the height of the mutated and wild-type nucleotide peaks on the
DNA chromatograms. The mutated nucleotide peak measurement
was divided by the sum of the mutated and wild-type peak
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measurements resulting in a percentage value for mutated DNA. In
the case of tandem point mutations, the proportion of mutated DNA
at each nucleotide was calculated and the two values averaged.
Statistical analysis
Tumors with complete sequence results for NRAS exon 2 and BRAF
exon 15 RGP, and VGP DNA were analyzed statistically using the
exact McNemar’s test of equality of paired proportions. The paired
t-test was utilized to compare the proportion of mutated DNA in the
RGP and the VGP of individual tumors exhibiting mutations in both
growth phases.
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